No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
KRYS Krystal Biotech
- 160.050
- -1.550-0.96%
Close May 31 16:00 ET
- 157.500
- -2.550-1.59%
Post 17:17 ET
4.57BMarket Cap73.42P/E (TTM)
163.980High158.610Low187.58KVolume161.130Open161.600Pre Close30.05MTurnover0.89%Turnover Ratio410.38P/E (Static)28.56MShares189.97052wk High5.72P/B3.36BFloat Cap93.95052wk Low--Dividend TTM20.99MShs Float189.970Historical High--Div YieldTTM3.32%Amplitude8.030Historical Low160.217Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Krystal Biotech (KRYS) and Veeva Systems (VEEV)
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
How Is The Market Feeling About Krystal Biotech?
Krystal Biotech's (NYSE:KRYS) short percent of float has risen 5.73% since its last report. The company recently reported that it has 2.59 million shares sold short, which is 12.0% of all regular shar
Earnings Estimates Moving Higher for Krystal Biotech (KRYS): Time to Buy?
Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why
Comments
The strong revenue growth is mirrored in the share price gain. Despite the strong run, top performers like Krystal Biotech can continue winning for decades. The stock's recent performance improvement may suggest real business momentum.
Investing in Krystal Biotech (NASDAQ:KRYS) Five Years Ago Would Have Delivered You a 389% Gain 1
High insider ownership at Krystal Biotech implies management's alignment with shareholders. Yet, no insider transactions in the last three months and significant share selling over the past year are concerning.
Analysts' optimism soars as they forecast Krystal Biotech to break even soon, given its massive projected annual growth rate of 68%. The firm's debt-free operation, unusual in loss-making biotech companies, lowers investment risk.
Market rewards Krystal Biotech's significant revenue growth despite recent stock price decline. Bullish sentiment suggests ongoing positive trend, irrespective of the current drop.
Despite the substantial selling of shares over the past year, insiders' ownership is still considerable. However, the lack of recent insider purchases could be of concern. Investors are advised to also consider the potential risks facing Krystal Biotech.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg